Inhibikase Therapeutics GAAP EPS of -$0.15
Source: SeekingAlpha
2025-05-15 11:56:29 ET
More on Inhibikase Therapeutics
- Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH
- Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise
- Seeking Alpha’s Quant Rating on Inhibikase Therapeutics
- Historical earnings data for Inhibikase Therapeutics
- Financial information for Inhibikase Therapeutics
Read the full article on Seeking Alpha
For further details see:
Inhibikase Therapeutics GAAP EPS of -$0.15
Inhibikase Therapeutics Inc.
NASDAQ: IKT
IKT Trading
5.95% G/L:
$1.96 Last:
1,145,833 Volume:
$1.86 Open:
IKT Latest News
August 14, 2025 04:50:16 pm
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
IKT Stock Data
$312,546,783
59,068,475
3.59%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington
